Follistatin 344 vs YK11: separating hype from hard science

What did @sethjordan3.000 actually say?

The creator compared YK11 and follistatin 344 as myostatin inhibitors, arguing both build muscle "beyond the limits." The core claims: YK11 builds muscle by lowering myostatin while also acting as a partial SARM, tendon weakness is a real risk when myostatin is suppressed, and cycling YK11 short-term can "resensitize the androgen receptors." He also raised concerns about gene therapies that permanently lower myostatin in humans.

A few things to flag immediately: he consistently called the androgen receptor the "antigen receptor," which is a basic terminology error. He also referred to follistatin 344 as "thalostatin 344" at several points, suggesting either a script error or genuine unfamiliarity with the compound. These aren't minor slips when you're positioning yourself as an educator on regulated substances.

Does the science back this up?

Partially, but with significant gaps. The myostatin-muscle connection is real and well-documented. The tendon concern has legitimate biological grounding. But the evidence for YK11 in humans is essentially nonexistent, and the same goes for follistatin 344 as a standalone injectable in clinical use.

Myostatin, encoded by the MSTN gene, is a negative regulator of skeletal muscle mass. This is not controversial. Loss-of-function mutations in MSTN produce dramatic muscle hypertrophy in cattle, dogs, and a handful of documented human cases (Schuelke et al., 2004, New England Journal of Medicine). The tradeoff with connective tissue is also biologically plausible: myostatin signaling affects tendon fibroblasts, and animal models of myostatin inhibition show disproportionate tendon stress relative to muscle gains (Mendias et al., 2008, Journal of Applied Physiology). So the creator isn't inventing that concern.

YK11 is a synthetic steroidal compound studied in vitro by Kanno et al. (2011, Biological and Pharmaceutical Bulletin), who showed it induced myogenic differentiation partly via follistatin upregulation, which would suppress myostatin indirectly. That's one cell study. There are no published human trials on YK11 for muscle growth, safety, or anything else.

What did they get wrong (or right)?

Wrong: calling the androgen receptor the "antigen receptor" repeatedly is not a minor error. It signals a surface-level understanding of the mechanism being described. YK11 binds the androgen receptor, not an antigen receptor, and that distinction matters when explaining how SARMs differ from traditional androgens.

Wrong: the claim that YK11 "definitely works because the scientific studies show" it builds muscle is overstated. The Kanno 2011 data is in vitro only. There are no human RCTs. "Definitely works" is not a conclusion you can draw from cell culture data.

Partially right: the myostatin-tendon tradeoff is a legitimate concern with real mechanistic support. Mendias et al. showed that myostatin null mice had tendons with reduced stiffness and cross-sectional area relative to their muscle mass, creating an injury risk profile. The creator is right to flag this, even if the framing around gene therapy feels speculative.

Wrong: follistatin 344 is not a well-characterized injectable compound with a clean safety record. It is a research protein, not an approved therapeutic. Presenting it alongside YK11 as a comparable consumer choice skips over the fact that neither compound has cleared any regulatory pathway for human use.

What should you actually know?

If you're considering either of these compounds, the honest summary is: the biology is interesting, the human safety data is missing, and the regulatory status is clear. Neither YK11 nor follistatin 344 is approved by the FDA for any indication. YK11 is not classified as a SARM by the FDA but has been flagged in warning letters as an unapproved drug ingredient in supplements.

The myostatin biology the creator references is grounded in real science. Follistatin is a legitimate endogenous antagonist of myostatin and activin signaling, and researchers are actively exploring it in the context of muscle-wasting diseases (Rodino-Klapac et al., 2009, Journal of Translational Medicine). But "researchers are exploring this in disease contexts" is a very different statement from "this is something you should inject to get gains."

The tendon risk point deserves more weight than the creator gave it. If you're using something that meaningfully suppresses myostatin while your tendons lag behind your new muscle capacity, the injury risk is not theoretical. It's a biomechanical reality that serious sports medicine clinicians take seriously.

Anyone exploring peptide-based approaches to recovery or body composition should work with a licensed provider who can assess individual risk, not take cues from a TikTok comparison video that mispronounces both compounds in question.